Updated:
China National Biotec Group
China National Biotec Group was established in 1919. It functions as a corporate investor and manufacturer under parent Sinopharm. The firm focuses on...
China National Biotec Group
China National Biotec Group was established in 1919. It functions as a corporate investor and manufacturer under parent Sinopharm. The firm focuses on biological products such as vaccines, antibodies, and diagnostics. It has executed joint ventures including Sino-Innovax Biotech with Innova Medical Group and co-investments with Fosun Pharma. Operations span China with additional sites in Shanghai. No recent operational events from the last 24 months are recorded. The firm holds membership in the Developing Countries Vaccine Manufacturers Network. Its structure as a majority-owned subsidiary of Sinopharm shapes governance and capital deployment.
General information
Firm type
Corporate Investor
Year founded
1919
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
No. 2 Courtyard, Shuangqiao Road, Chaoyang District, Beijing, China
Additional offices
Shanghai, China
Sector focus
Frequently asked questions
Who owns China National Biotec Group?
Sinopharm holds 95% ownership of China National Biotec Group.
What does China National Biotec Group manufacture?
The firm produces human vaccines, therapeutic drugs, antibodies, and diagnostic products.
Does China National Biotec Group maintain partnerships with external organizations?
It has collaborated with the Bill & Melinda Gates Foundation on global health initiatives and formed a joint venture with Innova Medical Group.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: